✦ LIBER ✦

Vandetanib Versus Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

✍ Scribed by Natale, R. B.; Bodkin, D.; Govindan, R.; Sleckman, B. G.; Rizvi, N. A.; Capo, A.; Germonpre, P.; Eberhardt, W. E.E.; Stockman, P. K.; Kennedy, S. J.; Ranson, M.

Book ID: 125518992
Publisher: American Society of Clinical Oncology
Year: 2009
Tongue: English
Weight: 210 KB
Volume: 27
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2008.18.6015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

9005 Vandetanib versus erlotinib in pati

9005 Vandetanib versus erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

✍ Goss, G.D.; Thongprasert, S.; Greco, F.A.; Thomas, M.; Tsai, C.M.; Sunpaweravong 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

A Randomized Phase II Study of Gefitinib

A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

✍ Han, J.-Y.; Lee, S.-H.; Yoo, N. J.; Hyung, L. S.; Moon, Y. J.; Yun, T.; Kim, H. 📂 Article 📅 2011 🏛 American Association for Cancer Research 🌐 English ⚖ 317 KB

Randomized phase II study of gefitinib v

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy

✍ Kim, Seung Tae; Uhm, Ji Eun; Lee, Jeeyun; Sun, Jong-mu; Sohn, Insuk; Kim, Seon W 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 359 KB

9001 Vandetanib plus docetaxel versus do

9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

✍ Eberhardt, W.E.E.; Johnson, B.E.; Sun, Y.; Germonpré, P.; Saijo, N.; Zhou, C.; W 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Icotinib versus gefitinib in previously

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

✍ Shi, Yuankai; Zhang, Li; Liu, Xiaoqing; Zhou, Caicun; Zhang, Li; Zhang, Shucai; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 490 KB

Second-line therapy with gefitinib in co

Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study

✍ G. Robinet; F. Barlesi; P. Fournel; H. Berard; R. Corre; A. Vergnenegre; L. Falc 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 160 KB